^

Association details:

Evidence:

Evidence Level:
Sensitive: A1 - Approval
Title:
Health Canada Approves Biocon and Mylan’s Ogivri™, the First Trastuzumab Biosimilar, for the Treatment of HER2-Positive Breast and Gastric Cancers
Published date:
05/22/2019
Excerpt:
Biocon Ltd. and Mylan N.V. today announced that Health Canada has approved Mylan’s Ogivri™ (trastuzumab), a biosimilar to Herceptin1 (trastuzumab) co-developed with Biocon, for the treatment of HER2-overexpressing breast cancer and metastatic stomach cancer (gastric or gastroesophageal junction adenocarcinoma).
Evidence Level:
Sensitive: A1 - Approval
Source:
Excerpt:
Ogivri is a HER2/neu receptor antagonist indicated for...the treatment of HER2-overexpressing breast cancer.
Secondary therapy:
docetaxel + doxorubicin hydrochloride + cyclophosphamide oral; paclitaxel + doxorubicin hydrochloride + cyclophosphamide oral; carboplatin + docetaxel; paclitaxel
Evidence Level:
Sensitive: C2 – Inclusion Criteria
Title:
Study of Efficacy and Safety of Myl1401O + Taxane vs Herceptin©+ Taxane for 1st Line, Met. Br. Ca.
Excerpt:
...Documentation of HER2 gene amplification by fluorescent in situ hybridization (FISH) (as defined by a ratio >2.0) or documentation of HER2-overexpression by immunohistochemistry (IHC) (defined as IHC3+, or IHC2+ with FISH confirmation) based on the sponsor-identified central laboratory prior to randomization....
Trial ID:
Evidence Level:
Sensitive: D – Preclinical
New
Title:
Microwave-Assisted Chitosan-Functionalized Graphene Oxide as Controlled Intracellular Drug Delivery Nanosystem for Synergistic Antitumour Activity
Published date:
04/30/2021
Excerpt:
...safety and therapeutic efficacy in HER2-overexpressing BT-474 cells...The combined treatment of ChrGO/adriamycin and trastuzumab in BT-474 cells induced cell cycle arrest and apoptosis, which ultimately led to the death of augmented cancer cells.
Secondary therapy:
doxorubicin hydrochloride
DOI:
10.1186/s11671-021-03525-y
VERI is free for non-commercial use, no login needed.
Content on this site is for research purposes only and is not intended  to be a substitute for medical advice.
For commercial access, including additional premium features, please contact us.
By using VERI, you are agreeing to our